Sponsored by
Congratulations to our President, Al Musella, for joining the board of IQ-AI! The Musella Foundation has been helping Imaging Biometrics, a subsidiary of IQ-AI, fund and run an expanded access program for their glioblastoma drug candidate, oral gallium maltolate. Additionally, we are starting a new project using Imaging Biometrics' unique software, which creates Fractional Tumor Burden Maps from MRI scan data, to help monitor glioblastoma patients starting Optune so we can tell earlier if Optune is working for that patient or not!